In the News

The Pharmaletter

May 9, 2024

Part of a growing trend in the industry, Ligand Pharmaceuticals (Nasdaq: LGND) has inked a royalty financing agreement with immunology company Agenus (Nasdaq: AGEN).

OncLive

April 12, 2024

Updated findings from a phase 1 trial (NCT03860272) evaluating botensilimab (AGEN1181) plus balstilimab (AGEN2034) for the treatment of patients with refractory microsatellite-stable (MSS)/mismatch repair–proficient (pMMR) metastatic colorectal cancer (mCRC) show that the combination elicited 12- and 18-month overall survival (OS) rates of 71% and 62%, respectively.

Cancer Network

January 21, 2024

Neoadjuvant botensilimab plus balstilimab appears to be safe and effective in patients with colorectal cancer regardless of mismatch repair status in the phase 2 NEST-1 trial.

Forbes

September 20, 2023

A combination immunotherapy developed by biotech company Agenus administered before surgery destroyed over 80% of a tumor before it was removed.